Cancer Cell

Article	Citations
Accelerated approvals: Early-phase success or premature authorization?	1570
Characterization of the generic mutant p53-rescue compounds in a broad range of assays	776
KIT as a therapeutic target in neuroendocrine prostate cancer	511
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas	504
Diet-microbiome interactions in cancer	472
Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer	396
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer	374
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer	364
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling	353
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition	338
EGFR-activated myofibroblasts promote metastasis of pancreatic cancer	324
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations	317
Spatial profiling technologies illuminate the tumor microenvironment	316
Hand in hand to successful immunotherapy: CD8+ T cells and M1-like macrophages swap the baton	314
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients	293
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron	290
High endothelial venules in cancer: Regulation, function, and therapeutic implication	277
Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer	266
T cell dynamism and immune-related adverse events	266
T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation	261
B cell heterogeneity in cancer comes of age	261
Bacteria in metastatic sites: Unveiling hidden players in cancer progression	259
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer	255
The aging lung microenvironment awakens melanoma metastases	250
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma	243

A holistic view of cancer	234
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors	233
Challenges in neoantigen-directed therapeutics	232
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer	228
Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity	227
Cancer vaccines	224
Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses	218
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer	216
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer	213
Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer	209
Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion	208
Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin	206
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments	206
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma	204
Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics	204
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients	203
Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer	203
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma	191
Challenges and opportunities for modeling aging and cancer	186
Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population	186
Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma	185
Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma	184
Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation	182
Tumor organoid-originated biomarkers predict immune response to PD-1 blockade	181
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts	177
Gut microbes promote chemoradiotherapy resistance via metabolic cross-feeding	177
Tumor-directed dysregulation of erythroid progenitors drives immunosuppressive myeloid cells	177
The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors	175
Immunosensitivity cuts across mismatch repair status in colorectal cancer	174
Revisiting TNM staging for EBV-related nasopharyngeal carcinoma	174
Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?	173
A genetic portrait of metastatic seeds in lung adenocarcinoma	170
Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity	169
Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation	169
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy	168
Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver	167
Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification	166
Hypoxia inducible factor-1α drives cancer resistance to cuproptosis	162
Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer	161
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy	158
Dissecting bulk transcriptomes of diffuse large B cell lymphoma	145
Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade	144
ILC3 plasticity in microbiome-mediated tumor progression and immunotherapy	139
Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers	138
Integrated proteogenomic characterization of glioblastoma evolution	137
Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis	137
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1	136
Tumor-infiltrating lymphocytes: A new hope	135
Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma	133
Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions	132

Recognition of observer effect is required for rigor and reproducibility of preclinical animal studies	132
A path to translation: How 3D patient tumor avatars enable next generation precision oncology	130
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD	130
Immune determinants of the pre-metastatic niche	129
Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment	128
Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring	127
Midkine as a driver of age-related changes and increase in mammary tumorigenesis	127
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells	126
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma	125
Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells	124
Response-based molecular subtyping—emergence of the third generation of breast cancer subtypes	121
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness	120
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study	118
Taxanes directly induce T cell cytotoxic extracellular vesicles to eradicate tumor cells	116
T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers	116
Multiplex computational pathology for treatment response prediction	115
Tumors on different wavelengths	114
GDF15 research from bench to bedside	112
Firing up neutrophil anti-tumor immunity with cocktails	111
The winner takes it all: Competition drives clonal selection in gliomagenesis	111
A circular RNA in neuroendocrine carcinomas	110
Precise patient stratification in esophageal cancer: Biomarkers for immunochemotherapy	109
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial	108
JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma	108
New horizons at the interface of artificial intelligence and translational cancer research	108
Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance	107
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma	107
Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations	106
Distinct spatiotemporal dynamics of CD8+ T cell-derived cytokines in the tumor microenvironment	105
Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer	104
Proteogenomic data and resources for pan-cancer analysis	103
GD2-CAR T cells in patients with osteosarcoma and neuroblastoma—it’s not only the T cells that matter	102
Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma	102
Integrated single cell analysis reveals co-evolution of malignant B cells and tumor micro-environment in transformed follicular lymphoma	100
The promise and peril of KRAS G12C inhibitors	99
Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma	99
Lactobacillus reuteri—an old acquaintance takes on a new task in colorectal tumor surveillance	98
An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma	97
Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures	96
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia	96
Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer	96
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer	96
Tumor heterogeneity	95
Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers	95
Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer	95
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy	94
Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer	94
Seed or soil: Tracing the immune subsets in metastatic tumors	93
CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4	93
From intestinal metaplasia to gastric cancer: Witnessing the rise of evil over time and space	92
PD-1 blockade is a promising therapeutic addition to neoadjuvant chemoradiation in locally advanced rectal cancer	91
Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity	91
Plasma cell and cancer stem cell crosstalk in glioblastoma	90
Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy	89
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity	89
Bacteria and fungi: The counteracting modulators of immune responses to radiation therapy in cancer	89
Horizontal mitochondrial transfer in cancer biology: Potential clinical relevance	88
STAG2 mutations alter CTCF-anchored loop extrusion, reduce cis-regulatory interactions and EWSR1-FLI1 activity in Ewing sarcoma	88
Tumor microbiome links cellular programs and immunity in pancreatic cancer	88
Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy	88
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells	87
Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy	87
Stromal lipid species dictate melanoma metastasis and tropism	87
Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers	87
Glioblastoma induces the recruitment and differentiation of dendritic-like “hybrid” neutrophils from skull bone marrow	86
High-frequency temperature monitoring for early detection of febrile adverse events in patients with cancer	84
High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer	83
Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers	83
Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma	82
Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient	81
Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC	80
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer	80
Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot	80
Oncolytic virotherapy: Potentially a game-changing tumor treatment	80
Identification of specific PP2A complexes involved in human cell transformation	79
Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice	79
Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer	78
Architecture sets the path: Breast cancer subtypes differently shape the early brain metastatic niche	78
Vascular characterization reveals immunomodulatory targets for brain metastases	77
Revealing de novo pyrimidine synthesis as a key vulnerability in brain tumors	76

Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition	76
When immunotherapy meets surgery in non-small cell lung cancer	76
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative	75
Infiltrating plasma cells maintain glioblastoma stem cells through IgG-Tumor binding	75
Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer	74
Genomic mapping of metastatic organotropism in lung adenocarcinoma	73
Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trial	73
A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma	72
Spatiotemporal genomic profiling of intestinal metaplasia reveals clonal dynamics of gastric cancer progression	72
A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression	71
Molecular classification and diagnostics of upper urinary tract urothelial carcinoma	71
Overcoming melanoma therapy resistance with RAF-MEK and FAK inhibition	70
Metastatic urothelial carcinoma	69
Sex and cancer immunotherapy: Current understanding and challenges	69
The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy	68
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma	67
Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer	67
Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity	67
Bridging the gap: The future of cancer research and clinical oncology in Cancer Cell	65
Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance	64
IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy	64
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma	63
Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma	62
Carnobacterium maltaromaticum boosts intestinal vitamin D production to suppress colorectal cancer in female mice	62
Immune phenotypic linkage between colorectal cancer and liver metastasis	61
Neutrophil-activating therapy for the treatment of cancer	61
Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockade	59
T cell engagers in solid tumors kick the door down	58
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts	58
Molecular subtypes of upper tract urothelial cancer: Setting the stage for precision therapy	58
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity	58
Insights into the co-evolution of epithelial cells and fibroblasts in the esophageal tumor microenvironment	56
Metabolic regulation of Cathepsin B in tumor macrophages drives their pro-metastatic function	56
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells	55
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory	54
Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis	54
Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer	54
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)	53
IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment	53
Melanoma models for the next generation of therapies	52
Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer	52
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers	51
Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma	51
Senescent alveolar macrophages promote early-stage lung tumorigenesis	51
Of HIFs and hERVs: Neoantigen generation in kidney cancer	50
IgA transcytosis: A new weapon in the immune response to cancer?	50
COVID-19 provides an opportunity to transform cancer research	50
Innate lymphoid cells recruit T cells to turn up the heat on tumors	50
Cooperative CAR targeting to selectively eliminate AML and minimize escape	50
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy	50